Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Long-term follow-up of BRL-101 in people with beta-thalassemia

Follows people with transfusion-dependent beta-thalassemia after an infusion of BRL-101 over time.

Plain-language title generated from the registry record
Registry title: Long-term Follow-up Study of BRL-101 for TDT

Key facts

Where
Changsha, Guangxi, Guangzhou, Nanning, Shenzhen, and Tianjin, ChinaSee the 7 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with transfusion-dependent β-thalassemia who were already treated with BRL-101. It follows them over a long time to check safety and effect.

Age
3 Years to 35 Years
Sex
All sexes can join.
Disease stage
Transfusion-dependent β-thalassemia (TDT).
Earlier treatment
Must have been treated with BRL-101 for transfusion-dependent β-thalassemia.

Main reasons for not taking part

  • The record lists no exclusion criteria.

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 3 and 35 years old?

Source: NCT06298630, who can take part

Where in China

  • Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Bin Fu, PhDTaking people
  • The First Affiliated Hospital of Guangxi Medical UniversityGuangxi, ChinaContact: Yongrong Lai, PhDTaking people
  • Sun Yat Sen Memorial Hospital of Sun Yat sen UniversityGuangzhou, ChinaContact: Jianpei Fang, phDNot yet recruiting
  • Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaContact: Rongmei Liang, phDNo longer taking part
  • No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army HospitalNanning, ChinaContact: Xinhua Zhang, phDNot yet recruiting
  • Shenzhen Children's HospitalShenzhen, ChinaContact: Sixi Liu, phDNot yet recruiting
  • Tianjin Institute of HematologyTianjin, ChinaContact: Jun shi, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Bioray Laboratories
Trial code
NCT06298630
Record updated
21 July 2026
Original description
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.Read full original descriptionShow less

Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Inclusion: Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s); Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.

Exclusion: There are no exclusion criteria for this study.

ClinicalTrials.gov NCT06298630